Biden to send 4 million AstraZeneca vaccine doses to Canada and Mexico

Mexico would receive 2.5 million doses and Canada would receive 1.5 million doses

<p>Biden may insist on the two nations returning the favour later in the year</p>

Biden may insist on the two nations returning the favour later in the year

Leer en Español

The Biden administration has agreed to send surplus doses of the AstraZeneca vaccine to Mexico and Canada, according to senior administration officials.

The country plans to send 2.5 million Covid-19 vaccine doses to Mexico and 1.5 million to Canada to help fill vaccine shortfalls.

It would be the first formal commitment by the US to supply vaccines to other nations.

This virus has no borders,” an administration official told Reuters. “We only put the virus behind us if we’re helping our global partners.”

An agreement could be reached with Mexico as early as Friday.

“I’d say we’ve made good progress, but the details ... won’t be known until Friday,” Mexican foreign minister Marcelo Ebrard told reporters on Thursday morning. “We requested as many [AstraZeneca doses] as possible.”

The Biden administration has purchased 800 million doses from Moderna, Pfizer and Johnson & Johnson.

But President Biden has also revealed his commitment to assisting other countries in vaccinating their residents.

Read more:

Mexico and Canada lack the infrastructure to vaccinate their residents as swiftly as the US.

AstraZeneca has millions of vaccines ready to use in the US, but the drug maker has yet to apply for authorisation from the Food and Drug Administration (FDA).

Clinical trials are underway in the US for the vaccine.

Senior officials in the Biden administration told CNN that they were considering a deal where the US gives AstraZeneca vaccine doses to the two countries now with the understanding that Mexico and Canada could supply the country with excess vaccine doses in future months.

The news of the vaccine agreement comes as the European Medicines Agency has backed the continued usage of the Oxford-AstraZeneca vaccine in Europe following some concerns about safety.

“The committee has come to a clear scientific conclusion,” Emer Cooke, executive director of EMA said in a statement released on Thursday.

“This is a safe and effective vaccine, its benefits in protecting people from Covid-19 with the associated risks of death and hospitalisation outweigh the possible risks. The committee also concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots.”

Eighteen countries across Europe have suspended the use of the vaccine following reports linking the jabs to blood clots.

The Medicines and Healthcare Products Regulatory Agency, a UK health watchdog, insists the vaccine is safe.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in